Immunostimulatory oligonucleotides in therapy of allergic diseases

Bibliography

• ROMAGNANI S: Thl and Th2 in human diseases. Clin. Immunol Immunopathol (1996) 80:225–235.
   PubMedGoogle Scholar
• ••This review underlines the role of theThl.—Th2 balance in human pathologies, including allergic diseases.
   Google Scholar
• COLILLA S, NICOLAE D, PLUZHNIKOV A et al.: Evidence for gene-environment interactions in a linkage study of asthma and smoking exposure. J. Allergy Clin. Immunol (2003) 111:840–846.
   PubMed Web of Science ®Google Scholar
• MATRICARDI PM: Inner-city asthma and the hygiene hypothesis. Ann. Allergy Asthma Immunol (2002) 89:69–74.
   PubMed Web of Science ®Google Scholar
• MATRICARDI PM, ROSMINI F, FORTINI M, FERRIGNO L, RAPICETTA M, BONINI S: Exposure to foodborne and orofecal microbes versus airborne viruses in relation to atopy and allergic asthma: epidemiological study. Br. Med. J. (2000) 320:412–417.
   PubMed Web of Science ®Google Scholar
• GEHRING U, BOLTE G, BORTE M et al.: Exposure to endotoxin decreases the risk of atopic eczema in infancy: a cohort study. J. Allergy Clin. Immunol (2001) 108:847–854.
   PubMed Web of Science ®Google Scholar
• BRAUN-FAHRLANDER C, RIEDLER J, HERZ U et al.: Environmental exposure to endotoxin and its relation to asthma in school-age children. Allergy and Endotoxin Study Team. N Engl. J. Med. (2002) 347:869–877.
   PubMed Web of Science ®Google Scholar
• KEMP A, BJORKSTEN B: Immune deviation and the hygiene hypothesis: a review of the epidemiological evidence. Pediatr. Allergy ImmunoL (2003) 14:74–80.
   PubMed Web of Science ®Google Scholar
• MARTINEZ FD, HOLT PG: Role of microbial burden in etiology of allergy and asthma. Lancet (1999) 354:12–15.
   Google Scholar
• •This is one of the first reports concerning the role of microbial pathogens in the maturation of the immune system and the development of allergy.
   Google Scholar
• GRZELA K, LAZARCZYK M, DZIUNYCZ P, MILEWSKI L, NIDERLA J, GRZELA T: Molecular therapy versus standard treatment in allergy. Int. J. MoL Med. (2004) 14:3–22.
   PubMed Web of Science ®Google Scholar
• GRZELA K, LAZARCZYK M, GRZELAT: Nucleic acid-based molecular treatment of allergy. Curr. Med. Chem. Anti-Inflamm. Anti-Allergy Agents (2004) 3:63–73.
   Google Scholar
• •A comprehensive review of new strategies in allergy treatment.
   Google Scholar
• JANEWAY CA, MEDZHITOV R: Innate immune recognition. Annu. Rev. ImmunoL (2002) 20:197–216.
   PubMed Web of Science ®Google Scholar
• AKIRA S, TAKEDA K, KAISHO T: Toll-like receptors: critical proteins linking innate and acquired immunity. Nat. ImmunoL (2001) 2:675–680.
   PubMed Web of Science ®Google Scholar
• HASHIMOTO C, HUDSON KL, ANDERSON KV: The Toll gene of Drosophila, required for dorsal-ventral embryonic polarity, appears to encode a transmembrane protein. Cell (1988) 52:269–279.
   PubMed Web of Science ®Google Scholar
• LEMAITRE B, NICOLAS E, MICHAUT L, REICHHART JM, HOFFMAN JA: The dorsoventral regulatory gene cassette spatzle/Toll/cactus controls the potent antifitngal response in Drosophila adults. Cell (1996) 86:973–983.
   PubMed Web of Science ®Google Scholar
• •The first report indicating involvement of the Toll system in innate immunity.
   Google Scholar
• UHLMANN E, VOLLMER J: Recent advances in the development of immunostymulatory oligonucleotides. Curr. Opin. Drug Discov. DeveL (2003) 6:204-217. A comprehensive review, excellently describing the most important modifications of immunostimulatory oligonucleotides, as well as their major therapeutic applications.
   Google Scholar
• OPITZ B, SCHRODER NW, SPREITZER I et al.: Toll-like receptor 2 mediates Treponema glycolipid and lipoteichoic acid-induced NF-1(13 translocation. 1 Biol. Chem. (2001) 276:22041–22047.
   Google Scholar
• POLTORAK A, HEX, SMIRNOVA I et al.: Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in T1r4 gene. Science (1998) 282:2085–2088.
   PubMed Web of Science ®Google Scholar
• WERTS C, TAPPING RI, MATHISON JC et al.: Leptospiral liopolysaccharide activates cells through a TLR2-dependend mechanism. Nat. ImmunoL (2001) 2:346–352.
   PubMed Web of Science ®Google Scholar
• TAKEUCHI O, SATO S, HORIUCHI T et al.: Cutting edge: role of Toll-like receptor 1 in mediating immune response to microbial lipoproteins. J. ImmunoL (2002) 169:10–14.
   PubMed Web of Science ®Google Scholar
• SCHWANDNER R, DZIARSKI R, WESCHE H, ROTHE M, KIRSCHNING CJ: Peptidoglycan- and lipoteichoic acid-induced cell activation is mediated by Toll-like receptor 2.1 Biol. Chem. (1999) 274:17406–17409.
   Google Scholar
• HAYASHI F, SMITH KD, OZINSKY A et al.: The innate immune response to bacterial flagellin is mediated by Toll-like receptor-5. Nature (2001) 410:1099–1103.
   PubMed Web of Science ®Google Scholar
• HEIL F, HEMMI H, HOCHREIN H et al.: Species-specific recognition of single-stranded RNA via Toll-like receptor 7 and 8. Science (2004) 303:1526–1529.
   PubMed Web of Science ®Google Scholar
• ALEXOPOULOU L, HOLT AC, MEDZHITOV R, FLAVELL RA: Recognition of double-stranded RNA and activation of NF-KB by Toll-like receptor 3. Nature (2001) 413:732–738.
   PubMed Web of Science ®Google Scholar
• HEMMI H, TAKEUCHI O, KAWAI T et al.: A Toll-like receptor recognizes bacterial DNA. Nature (2000) 408:740–745.
   PubMed Web of Science ®Google Scholar
• BIRD AP: CpG islands as gene markers in the vertebrate nucleus. Trends Genet. (1987) 3:342–347.
   Web of Science ®Google Scholar
• KRIEG AM, YT AK, MATSON S et al.: CpG motifs in bacterial DNA trigger direct B-cell activation. Nature (1995) 374:546–549.
   PubMed Web of Science ®Google Scholar
• •A report characterising the immunostimulatory properties of CpG-containing DNA.
   Google Scholar
• KRIEG AM, WU T, WEERATNA R et al.: Sequence motifs in adenoviral DNA block immune activation by stimulatory CpG motifs. Proc. NatL Acad. Sci. USA (1998) 95:12631–12636.
   PubMed Web of Science ®Google Scholar
• ULEVITCH RJ: Therapeutics targeting the innate immune system. Nat. Rev. ImmunoL (2004) 4:512–520.
   PubMed Web of Science ®Google Scholar
• ••A comprehensive review describing themolecular aspects of innate immunity, as well as the main clinical applications of that knowledge.
   Google Scholar
• YAMAMOTO S, YAMAMOTO T, SHIMADA S et al.: DNA from bacteria, but not from vertebrates, induces interferones, activates natural killer cells and inhibits tumor growth. MicrobioL ImmunoL (1992) 36:983–997.
   PubMed Web of Science ®Google Scholar
• •One of the first papers to report immunostimulatory properties of bacterial DNA, in contrast to vertebrates' nucleic acids.
   Google Scholar
• KRIEG AM: CpG motifs in bacterial DNA and their immune effects. Annu. Rev. ImmunoL (2002) 20:709–760.
   PubMed Web of Science ®Google Scholar
• ••An excellent and comprehensive review ofall aspects of CpG oligonucleotides. The Bible for the CpG-ODN field researcher.
   Google Scholar
• KRUG A, ROTHENFUSSER S, HORNUNG Vet al.: Identification of CpG oligonucleotide sequences with high induction of IFN-a/13 in plasmacytoid dendritic cells. Eur. J. ImmunoL (2001) 31:2154–2163.
   Google Scholar
• SKINNER RB JR: Imiquimod. DermatoL Clin. (2003) 21:291–300.
   PubMed Web of Science ®Google Scholar
• BELL JK, MULLEN GE, LEIFER CA, MAZZONI A. DAVIES DR, SEGAL DM: Leucine-rich repeats and pathogen recognition in Toll-like receptors. Trends ImmunoL (2003) 24:528–533.
   PubMed Web of Science ®Google Scholar
• AKIRA S, TAKEDA K: Toll-like receptor signaling. Nat. Rev. ImmunoL (2004) 4:499–511.
   PubMed Web of Science ®Google Scholar
• ••Excellent review focusing on the molecularaspects of TER-mediated signalling.
   Google Scholar
• AHMAD-NEJAD P, HACKER H, RUTZ M, BAUER S, VABULAS RM, WAGNER H: Bacterial CpG-DNA and lipopolysaccharides activate Toll-like receptors at distinct cellular compartments. Eur. J. ImmunoL (2002) 32:1958–1968.
   PubMed Web of Science ®Google Scholar
• MATSUMOTO M, FUNAMI K, TANABE M et al.: Subcellular localization of Toll-like receptor 3 in human dendritic cells. J. ImmunoL (2003) 171:3154–3162.
   PubMed Web of Science ®Google Scholar
• HEIL F, AHMAD-NEJAD P, HEMMI H et al.: The Toll-like receptor 7 (TLR7)-specific stimulus loxoribine uncovers a strong relationship within the TLR7, 8 and 9 subfamily. Eur. j Immunol (2003) 33:2987–2997.
   PubMed Web of Science ®Google Scholar
• LATZ E, SCHOENEMEYER A, VISINTIN A et al.: TLR9 signals after translocating from the ER to CpG DNA in the lysosome. Nat. Immunol (2004) 5:190–198.
   PubMed Web of Science ®Google Scholar
• O'NEIL LA, FITZGERALD KA, BOWIE AG: The Toll-IL-1 receptor adaptor family grows to five members. Trends Immunol (2003) 24:286–290.
   PubMedGoogle Scholar
• LI S, STRELOW A, FONTANA EJ, WESCHE H: IRAK-4: a novel member of the IRAK family with the properties of an IRAK-kinase. Proc. Nail. Acad. Sci. USA (2002) 99:5567–5572.
   PubMed Web of Science ®Google Scholar
• BRADLEY JR, POBER JS: Tumor necrosis factor receptor-associated factors (TRAFs). Oncogene (2001) 20:6482–6491.
   PubMedGoogle Scholar
• PARK Y, CHANG YS, LEE SW et ell.: The enhanced effect of a hexameric deoxyriboguanosine run conjugation to CpG oligodeoxynucleotides on protection against allergic asthma. J. Allergy Clin. Immunol (2001) 108:570–576.
   Google Scholar
• STORNI T, RUEDL C, SCHWARZ K, SCHWENDENER RA, RENNER WA, BACHMANN MF: Nonmethylated CG motifs packaged into virus-like particles induce protective cytotoxic T cell responses in the absence of systemic side effects. J. Immunol (2004) 172:1777–1785.
   PubMed Web of Science ®Google Scholar
• KLINE JN, WALDSCHMIDT TJ, BUSINGA TR et al.: Modulation of airway inflammation by CpG oligodeoxynucleotides in a murine model of asthma. J. Immunol (1998) 160:2555–2559.
   PubMed Web of Science ®Google Scholar
• PENG Z, WANG H, MAO X, HAYGLASS KT, SIMONS FE: CpG oligodeoxynucleotide vaccination suppresses IgE induction but may fail to down-regulate ongoing IgE responses in mice. Int. Immunol (2001) 13:3–11.
   PubMed Web of Science ®Google Scholar
• ZHU FG, KANDIMALLA ER, YU D, TANG JX, AGRAWAL S: Modulation of ovalbumin-induced Th2 responses by second-generation immunomodulatory oligonucleotides in mice. Int. Immunopharmacol (2004) 4:851–862.
   PubMed Web of Science ®Google Scholar
• AGRAWAL DK, EDWAN J, KANDIMALLA ER et al.: Novel immunomodulatory oligonucleotides prevent development of allergic airway inflammation and airway hyperresponsiveness in asthma. Int. Immunopharmacol (2004) 4:127–138.
   PubMed Web of Science ®Google Scholar
• BANERJEE B, KELLY KJ, FINK JN, HENDERSON JD JR, BANSAL NK, KURUP VP: Modulation of airway inflammation by immunostimulatory CpG oligodeoxynucleotides in a murine model of allergic aspergillosis. Infect. Immun. (2004) 72:6087–6094.
   PubMed Web of Science ®Google Scholar
• JAIN VV, KITAGAKI K, BUSINGA T et al.: CpG-oligodeoxynucleotides inhibit airway remodeling in a murine model of chronic asthma. J. Allergy Clin. Immunol (2002) 110:867–872.
   PubMed Web of Science ®Google Scholar
• SEREBRISKY D, TEPER AA, HUANG CK et al.: CpG oligodeoxynucleotides can reverse Th2-associated allergic airway responses and alter the B7.1/87.2 expression in a murine model of asthma. J. Immunol (2000) 165:5906–5912.
   Google Scholar
• BROIDE D, SCHWARZE J, TIGHE H et al.: Immunostimulatory DNA sequences inhibit IL-5, eosinophilic inflammation, and airway hyperresponsiveness in mice. Immunol (1998) 161:7054–7062.
   Web of Science ®Google Scholar
• IKEDA RK, NAYAR J, CHO JY et ell.: Resolution of airway inflammation following ovalbumin inhalation: comparison of ISS DNA and corticosteroids. Am. J. Respir. Cell Mol Biol. (2003) 28:655–663.
   Google Scholar
• FANUCCHI MV, SCHELEGLE ES, BAKER GL et al.: Immunostimulatory oligonucleotides attenuate airways remodeling in allergic monkeys. Am. J. Respir. Crit. Care Med. (2004) 170:1153–1157.
   PubMed Web of Science ®Google Scholar
• SUR S, WILD JS, CHOUDHURY BK, SUR N, ALAM R, KLINMAN DM: Long term prevention of allergic lung inflammation in a mouse model of asthma by CpG oligodeoxynucleotides. J. Immunol (1999) 162:6284–6293.
   PubMed Web of Science ®Google Scholar
• JAIN VV, BUSINGA TR, KITAGAKI K, GEORGE CL, O'SHAUGHNESSY PT, KLINE JN: Mucosal immunotherapy with CpG oligodeoxynucleotides reverses a murine model of chronic asthma induced by repeated antigen exposure. Am. J. PhysioL Lung Cell. MoL Physiol (2003) 285:L1137–L1146.
   PubMed Web of Science ®Google Scholar
• KOHAMA Y, AKIZUKI O, HAGIHARA K, YAMADA E, YAMAMOTO H: Immunostimulatory oligodeoxynucleotide induces TH1 immune response and inhibition of IgE antibody production to cedar pollen allergens in mice. J. Allergy Clin. Immunol (1999) 104:1231–1238.
   PubMed Web of Science ®Google Scholar
• SHIROTA H, SANO K, KIKUCHI T, TAMURA G, SHIRATO K: Regulation of T-helper type 2 cell and airway eosinophilia by transmucosal coadministration of antigen and oligodeoxynucleotides containing CpG motifs. Am. J. Respir. Cell. MoL Biol. (2000) 22:176–182.
   PubMed Web of Science ®Google Scholar
• BURGER MS, ZULEGER CL, CHU Q, GAO X, PAYNE LG, CHEN D: An antigen-independent but not antigen-specific TH1 response provides protection in the murine airway inflammation model. J. Allergy Clin. Immunol (2004) 114:1301–1308.
   PubMed Web of Science ®Google Scholar
• BROIDE DH, STACHNICK G, CASTANEDA D et al.: Systemic administration of immunostimulatory DNA sequences mediates reversible inhibition of Th2 responses in a mouse model of asthma. J. Clin. Immunol (2001) 21:175–182.
   PubMedGoogle Scholar
• YOUN CJ, MILLER M, BAEK KJ et al.:Immunostimulatory DNA reverses established allergen-induced airway remodeling. J. Immunol (2004) 173:7556–7564.
   PubMed Web of Science ®Google Scholar
• RHEE CS, LIBET L, CHISHOLM D et al.: Allergen-independent immunostimulatory sequence oligodeoxynucleotide therapy attenuates experimental allergic rhinitis. Immunology (2004) 113:106–113.
   PubMed Web of Science ®Google Scholar
• MAGONE MT, CHAN CC, BECK L, WHITCUP SM, RAZ E: Systemic or mucosal administration of immunostimulatory DNA inhibits early and late phases of murine allergic conjunctivitis. Eur. J. Immunol (2000) 30:1841–1850.
   PubMed Web of Science ®Google Scholar
• MIYAZAKI D, LIU G, CLARK L, ONO SJ: Prevention of acute allergic conjunctivitis and late-phase inflammation with immunostimulatory DNA sequences. Invest. Ophthalmol Vis. Sci. (2000) 41:3850–3855.
   PubMed Web of Science ®Google Scholar
• KLINE JN, KRIEG AM, WALDSCHMIDT TJ, BALLAS ZK, JAIN V, BUSINGA TR: CpG oligodeoxynucleotides do not require TH1 cytokines to prevent eosinophilic airway inflammation in a murine model of asthma. J. Allergy Clin. Immunol (1999) 104:1258–1264.
   PubMed Web of Science ®Google Scholar
• CHOUDHURY BK, WILD JS, ALAM R et al.: In vivo role of p38 mitogen-activated protein kinase in mediating the anti-inflammatory effects of CpG oligodeoxynucleotide in murine asthma. Immunol (2002) 169:5955–5961.
   Web of Science ®Google Scholar
• ZHU FG, PISETSKY DS: Role of the heat shock protein 90 in immune response stimulation by bacterial DNA and synthetic oligonucleotides. Infect. Immun. (2001) 69:5546–5552.
   PubMed Web of Science ®Google Scholar
• VISSERS JL, VAN ESCH BC, JEURINK PV, HOFMAN GA, VAN OOSTERHOUT AJ: Stimulation of allergen-loaded macrophages by TLR9-ligand potentiates IL-10-mediated suppression of allergic airway inflammation in mice. Respir. Res. (2004) 5(1):21.
   PubMedGoogle Scholar
• CHIANG DJ, YE YI,, CHEN WL, LEE YL, HSU NY, CHIANG BL: Ribavirin or CpG DNA sequence-modulated dendritic cells decrease the IgE level and airway inflammation. Am. J. Respir. Crit. Care Med. (2003) 168:575–580.
   PubMed Web of Science ®Google Scholar
• JAHN-SCHMID B, WIEDERMANN U, BOHLE B, REPA A, KRAFT D, EBNER C: Oligodeoxynucleotides containing CpG motifs modulate the allergic TH2 response of BALB/c mice to Bet v 1, the major birch pollen allergen. J. Allergy Clin. Immunol (1999) 104:1015–1023.
   PubMed Web of Science ®Google Scholar
• HORNER AA, TAKABAYASHI K, BECK L et al.: Optimized conjugation ratios lead to allergen immunostimulatory oligodeoxynucleotide conjugates with retained immunogenicity and minimal anaphylactogenicity. J. Allergy Clin. Immunol (2002) 110:413–420.
   PubMed Web of Science ®Google Scholar
• TIGHE H, TAKABAYASHI K, SCHWARTZ D et al.: Conjugation of immunostimulatory DNA to the short ragweed allergen amb a 1 enhances its immunogenicity and reduces its allergenicity. J. Allergy Clin. Immunol (2000) 106(1 Pt 1):124–134.
   Google Scholar
• TAKABAYASHI K, LIBET L, CHISHOLM D, ZUBELDIA J, HORNER AA: Intranasal immunotherapy is more effective than intradermal immunotherapy for the induction of airway allergen tolerance in Th2-sensitized mice. Immunol (2003) 170:3898–3905.
   Web of Science ®Google Scholar
• HORNER AA, RAZ E: Immunostimulatory sequence oligodeoxynucleotide-based vaccination and immunomodulation: two unique but complementary strategies for the treatment of allergic diseases./ Allergy Clin. Immunol (2002) 110:706–712.
   PubMed Web of Science ®Google Scholar
• SHIROTA H, SANO K, HIRASAWA N et al.: Novel roles of CpG oligodeoxynucleotides as a leader for the sampling and presentation of CpG-tagged antigen by dendritic cells. J. Immunol (2001) 167:66–74.
   PubMed Web of Science ®Google Scholar
• SANTEUZ JV, VAN NEST G, TRAQUINA P, LARSEN E, WILLS-KARP M: Amb a 1-linked CpG oligodeoxynucleotides reverse established airway hyperresponsiveness in a murine model of asthma. J. Allergy Clin. Immunol (2002) 109:455–462.
   PubMed Web of Science ®Google Scholar
• FARKAS L, KVALE EO, JOHANSEN FE, JAHNSEN FL, LUND-JOTANSEN F: Plasmacytoid dendritic cells activate allergen-specific TH2 memory cells: modulation by CpG oligodeoxynucleotides. J. Allergy Clin. Immunol (2004) 114:436–443.
   PubMed Web of Science ®Google Scholar
• MOSEMAN EA, LIANG X, DAWSON AJ et al.: Human plasmacytoid dendritic cells activated by CpG oligodeoxynucleotides induce the generation of CD4+CD25+ regulatory T cells. J. Immunol (2004) 173:4433–4442.
   PubMed Web of Science ®Google Scholar
• MARSHALL JD, ABTAHI S, EIDEN JJ et al.: Immunostimulatory sequence DNA linked to the Amb a 1 allergen promotes T(H)1 cytokine expression while downregulating T(H)2 cytokine expression in PBMCs from human patients with ragweed allergy. J. Allergy Clin. Immunol (2001) 108:191–197.
   PubMed Web of Science ®Google Scholar
• CRETICOS PS, EIDEN JJ, BALCER SL et al.: Immunostimulatory oligonucleotides conjugated to Amb a 1: Safety, skin test reactivity, and basophil histamine release. J. Allergy Clin. Immunol (2000) 105:S70.
   Web of Science ®Google Scholar
• CRETICOS PS, BALCER SL, SCHROEDER JT et al.: Initial immunotherapy trial to explore the safety tolerability and immunogenicity of subcutaneous injections of an AMB a 1 immunostimulatory oligonucleotide conjugate (AIC) in ragweed allergic adults. J. Allergy Clin. Immunol (2001) 107:S216.
   Web of Science ®Google Scholar
• CRETICOS PS, EIDEN JJ, BROIDE D et al.: Immunotherapy with immunostimulatory oligonucleotides linked to purified ragweed Amb a 1 allergen: effects on antibody production, nasal allergen provocation, and ragweed seasonal rhinitis. J. Allergy Clin. Immunol (2002) 109:743–744.
   Web of Science ®Google Scholar
• SIMONS FE, SHIKISHIMA Y, VAN NEST G, EIDEN JJ, HAYGLASS KT: Selective immune redirection in humans with ragweed allergy by injecting Amb a 1 linked to immunostimulatory DNA. J. Allergy Clin. Immunol (2004) 113:1144–1151.
   PubMed Web of Science ®Google Scholar
• TULIC MK, FISET PO, CHRISTODOULOPOULOS P et al.: Amb a 1-immunostimulatory oligodeoxynucleotide conjugate immunotherapy decreases the nasal inflammatory response. J. Allergy Clin. Immunol (2004) 113:235–241.
   PubMed Web of Science ®Google Scholar
• HOLGATE ST: The epidemic of allergy and asthma. Nature (1999) 402(6760 Suppl.):B2–B4.
   Google Scholar
• GRZELA K, LAZARCZYK M, GRZELA T: Protein-based strategies of molecular therapy in allergy. Curr. Med. Chem. Anti-Inflamm. Anti-Allergy Agents (2004) 3:53–62.
   Google Scholar
• AKIBA H, SATOH M, IWATSUKI K, KAISERLIAN D, NICOLAS JF, KANEKO F: CpG immunostimulatory sequences enhance contact hypersensitivity responses in mice. J. Invest. Dermatol (2004) 123:488–493.
   PubMed Web of Science ®Google Scholar
• CONANT SB, SWANBORG RH: Autoreactive T cells persist in rats protected against experimental autoimmune encephalomyelitis and can be activated through stimulation of innate immunity. Immunol (2004) 172:5322–5328.
   Web of Science ®Google Scholar
• DARABI K, KARULIN AY, BOEHM BO et al.: The third signal in T cell-mediated autoimmune disease? J. Immunol (2004) 173:92–99.
   Web of Science ®Google Scholar
• SCHLUESENER HJ, SEID K, DEININGER M, SCHWAB J: Transient in vivo activation of rat brain macrophages/ microglial cells and astrocytes by immunostimulatory multiple CpG oligonucleotides. j Neuroimmunol (2001) 113:89–94.
   PubMed Web of Science ®Google Scholar
• ILIEV Al, STRINGARIS AK, NAU R, NEUMANN H: Neuronal injury mediated via stimulation of microglial toll-like receptor-9 (TLR9). FASEB J. (2004) 18:412–414.
   PubMedGoogle Scholar
• HASEGAWA K, HAYASHI T: SyntheticCpG oligodeoxynucleotides accelerate the development of lupus nephritis during preactive phase in NZB x NZWF1 mice. Lupus (2003) 12:838–845.
   PubMed Web of Science ®Google Scholar
• HAYASHI T, YOSHINAKA K, HASEGAWA K, MAEDA K, ONODERA T: CpG oligodeoxynucleotides accelerate reovirus type 2-triggered insulitis in DBA/1 suckling mice. Int. J. Exp. PathoL (2002) 83:217–223.
   PubMed Web of Science ®Google Scholar
• LANG KS, RECHER M, JUNT T et al.:Toll-like receptor engagement converts T-cell autoreactivity into overt autoimmune disease. Nat. Med. (2005) 11:138–145.
   PubMed Web of Science ®Google Scholar
• BOKAREWA MI, HELLSTRAND K, TARKOWSKI A: Phosphorotioated oligonucleotides trigger synthesis of human coagulation serine proteases. Thromb. Haemost. (2002) 88:788–793.
   PubMed Web of Science ®Google Scholar
• VERTHELYI D, KLINMAN DM: Immunoregulatory activity of CpG oligonucleotides in humans and nonhuman primates. Clin. ImmunoL (2003) 109:64–71.
   PubMed Web of Science ®Google Scholar
• HEIKENWALDER M, POLYMENIDOU M, JUNT T et al.: Lymphoid follicle destruction and immunosuppression after repeated CpG oligodeoxynucleotides administration. Nat. Med. (2004) 10:187–192.
   PubMed Web of Science ®Google Scholar
• ••This paper reports the immunosuppressive mode of in vivo CpG-ODN action. Moreover, several serious adverse effects associated with CpG-ODN administration were presented.
   Google Scholar